EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

被引：0
|
作者：
Borba, H. H. [1 ]
Rochau, U. [2 ]
Wiens, A. [1 ]
Sroczynski, G. [2 ]
Siebert, U. [3 ]
Pontarolo, R. [1 ]
机构：
[1] Univ Fed Parana, Curitiba, Parana, Brazil
[2] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & HTA, Dept Publ Hlth Hlth Serv Res & HTA, Hall In Tirol, Austria
[3] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2627
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI9
引用
收藏
页码：A883 / A883
页数：1
相关论文
共 50 条
  • [21] Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
    Al-Bawardy, Badr
    Kim, W. Ray
    Poterucha, John J.
    Gross, John B.
    Charlton, Michael R.
    Larson, Joseph J.
    Colby, Colin L.
    Canterbury, Kathy
    Warner, Jennifer
    Therneau, Terry M.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (05) : 595 - 601
  • [22] Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elbasha E.H.
    Chhatwal J.
    Ferrante S.A.
    El Khoury A.C.
    Laires P.A.
    Applied Health Economics and Health Policy, 2013, 11 (1) : 65 - 78
  • [23] BOCEPREVIR AND TELAPREVIR EFFECTIVENESS AND SAFETY IN A BRAZILIAN COHORT OF CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS: A MULTICENTRIC LONGITUDINAL STUDY
    Borba, H. H.
    Wiens, A.
    Steimbach, L. M.
    Tonin, F. S.
    Pedroso, M. L.
    Minowa, E.
    Piedade, A.
    Clark, O.
    Fernandez-Llimos, F.
    Pontarolo, R.
    VALUE IN HEALTH, 2017, 20 (09) : A882 - A882
  • [24] Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
    Moradpour, Darius
    Muellhaupt, Beat
    SWISS MEDICAL WEEKLY, 2012, 142
  • [25] Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
    Saxena, V.
    Manos, M. M.
    Yee, H. S.
    Catalli, L.
    Wayne, E.
    Murphy, R. C.
    Shvachko, V. A.
    Pauly, M. P.
    Chua, J.
    Monto, A.
    Terrault, N. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1213 - 1224
  • [26] Evaluating the cost-effectiveness of using boceprevir and telaprevir in the treatment of newly diagnosed Hepatitis C genotype 1 patients: A payer's perspective.
    Jalundhwala, Yash J.
    Patel, Pankaj
    Nancy, Hedlund
    Wendy, Cheng
    Beenish, Manzoor
    Haridarshan, Patel
    Touchette, Daniel
    PHARMACOTHERAPY, 2012, 32 (10): : E300 - E301
  • [27] Cost-effectiveness analysis of telaprevir triple therapy for treatment-naive patients with chronic hepatitis C based on the combined efficacy data of the ADVANCE and OPTIMIZE studies
    Buti, Maria
    Gros, Blanca
    Oyagueez, Itziar
    Andrade, Raul J.
    Angel Serra, Miguel
    Turnes, Juan
    Casado, Miguel A.
    HEPATOLOGY, 2013, 58 : 1133A - 1133A
  • [28] COST-EFFECTIVENESS ANALYSIS OF THE ASPERGILLUS GALACTOMANNAN ENZYME IMMUNOASSAY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Barros, B.
    Magliano, C.
    Morais, Q. C.
    Leite, B. R.
    Leite, L. F. D. A.
    Mateus, I
    Braga, A.
    Santos, M.
    VALUE IN HEALTH, 2023, 26 (06) : S62 - S62
  • [29] COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Garay Ulises, U.
    McMullen, M.
    Rey Ares, L.
    Peirano, I
    Bessone, F.
    Fainboim, H.
    Gadano, A.
    Galdame, O.
    Vujacich, C.
    Caporale, J.
    VALUE IN HEALTH, 2013, 16 (07) : A692 - A692
  • [30] Cost-Effectiveness of Telaprevir in Patients with Genotype 1 Hepatitis C in Australia
    Warren, Emma
    Wright, Alison
    Jones, Brandon
    VALUE IN HEALTH, 2014, 17 (08) : 792 - 800
12345